Badve et al. [12] and Doria et al. [13] reported no significant difference in eGFR decline between allopurinol and placebo, with the latter even noting a paradoxical 40% increase in urinary albumin excretion, suggesting that urate-lowering alone may not suffice to modify CKD progression in certain subgroups. This evidence concerns the gene ALB and chronic kidney disease.